HCM
CLVS

Highbridge Capital Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Highbridge Capital Management’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-50,266
Closed -$3.42M – 1846
2017
Q4 		$3.42M Buy
50,266
+266
+0.5% +$18.6K 0.06% 311
2017
Q3 		$4.12M Buy
50,000
+39,200
+363% +$3.11M 0.06% 326
2017
Q2 		$1.01M Sell
10,800
-1,069
-9% -$65.4K 0.02% 568
2017
Q1 		$755K Buy
11,869
+1,869
+19% +$114K 0.01% 730
2016
Q4 		$444K Sell
10,000
-2,015
-17% -$70.9K 0.01% 812
2016
Q3 		$433K Buy
+12,015
New +$258K 0.01% 848
2016
Q2 		– Sell
-11,057
Closed -$212K – 1843
2016
Q1 		$212K Buy
+11,057
New +$234K ﹤0.01% 1317

Other funds holding CLVS

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return